- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01038804
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is an outpatient study. All subjects enrolled in this study will receive a combined regimen of YM155 and docetaxel or docetaxel alone given during 21 day cycles. Each subject will be assessed at the end of each cycle to determine if the subject can continue to the next cycle. Each subject assigned to receive YM155 in combination with docetaxel will be eligible to continue receiving the combination regimen in this study until one of the discontinuation criteria is met.
If a subject discontinues treatment with at least stable disease (SD) that subject will complete follow-up visits every 12 weeks for 2 years or until initiating another systemic anti-breast cancer treatment, exhibiting progressive disease (PD), or death.
Each subject will be contacted by the study site every 12 weeks for survival following the End of Treatment Visit. The contacts will continue until death or for no more than 2 years.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Brussels, Belgien, 1000
- Institut Jules Bordet - Medical Oncology and Translational Research
-
Charleroi, Belgien, 6000
- Grand Hôpital de Charleroi - Site Notre Dame
-
Wilrijk, Belgien, 2610
- Sint-Augustinus GZA Ziekenhuizen
-
-
-
-
California
-
Los Angeles, California, Förenta staterna, 90057
- Kenmar Research Institute
-
Pleasant Hill, California, Förenta staterna, 94523
- Bay Area Cancer Research Group
-
-
Florida
-
Lakeland, Florida, Förenta staterna, 33805
- Lakeland Regional Cancer Center
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48201
- Karmanos Cancer Institute
-
-
Montana
-
Missoula, Montana, Förenta staterna, 59802
- Montana Cancer Institute Foundation c/o Montana Cancer Specialists
-
-
North Carolina
-
Hickory, North Carolina, Förenta staterna, 28602
- Carolina Oncology Specialists, PA
-
-
Ohio
-
Canton, Ohio, Förenta staterna, 44718
- Gabrail Cancer Center
-
-
-
-
-
Dublin, Irland, 8
- St. James Hospital
-
Dublin, Irland, 4
- St. Vincent's University Hospital
-
Dublin, Irland, 9
- Department of Medical Oncology
-
-
-
-
-
Warsaw, Polen, 02-781
- Centrum Onkologii-Instytut im.
-
Wroclaw, Polen, 51-124
- Wojewodzki Szpital
-
-
-
-
-
Chelyabinsk, Ryska Federationen, 454076
- State Therapeutic and Prophylactic Institution Chelyabinsk Regional Clinical Oncology Dispensary
-
Kursk, Ryska Federationen, 305035
- State Healthcare institution "Kursk Regional Oncology Dispensary" of Kursk Region Healthcare committee GUZ "KOOD"
-
Moscow, Ryska Federationen, 115478
- Institution of Russian Academy of Medical Sciences Russian Oncology Research Centre
-
Pyatigorsk, Ryska Federationen, 357500
- Pyatigorsk Oncology Dispensary
-
Saint Petersburg, Ryska Federationen, 189646
- Scientific-Research Institute of Oncology named after Petrov
-
Saint Petersburg, Ryska Federationen, 197022
- Saint-Petersburg State Medical University named after Pavlov
-
Samara, Ryska Federationen, 443031
- State Healthcare Institution "Samara Regional Clinical Oncology Dispensary"
-
Tula, Ryska Federationen, 300053
- Tula Regional Dispensary
-
-
-
-
-
Nottingham, Storbritannien, NG5 1PB
- Nottingham University Hospital
-
-
-
-
-
Prague, Tjeckien, 180 81
- Faculty hospital Na Bulovce
-
Prague 10, Tjeckien, 100 34
- FN Kralovske Vinohrady
-
-
-
-
-
Augsburg, Tyskland, 86150
- Hämatologisch-Onkologische Praxis
-
Erlangen, Tyskland, 91054
- Frauenklinik des Universitätsklinikums Erlangen
-
Kiel, Tyskland, 24105
- Universitätsklinikum Schleswig
-
Trier, Tyskland, 54290
- Klinikum Mutterhaus der Borromaeerinnen
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Histologically- or cytologically-proven adenocarcinoma of the breast that is HER2 negative. Subjects with hormone receptor positive or negative status are eligible. Additionally, subjects with triple negative status (meaning estrogen receptor negative, progesterone receptor negative and HER2 negative) are eligible
- No prior chemotherapy regimen for metastatic breast cancer
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 at the Baseline Visit
- The subject's life expectancy is estimated to be > 12 weeks at the Baseline Visit
- The subject must be non-pregnant and non-lactating. All sexually active subjects of childbearing potential must agree to use an adequate method of contraception throughout the study period
Exclusion Criteria:
- Hypersensitivity to docetaxel or polysorbate 80
- Neuropathy ≥ Grade 2 at the Baseline Visit
- Known brain or leptomeningeal metastasis as assessed through medical history review and physical examination
- The subject has known Human Immunodeficiency Virus (HIV), Hepatitis B surface Antigen or hepatitis C antibody
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: A. YM155 plus docetaxel
|
intravenös infusion
intravenös infusion
Andra namn:
|
Aktiv komparator: B. docetaxel alone
|
intravenös infusion
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Progression free survival (PFS)
Tidsram: At the time of progression or death or at 2 year follow up
|
At the time of progression or death or at 2 year follow up
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Objective response rate (proportion of subjects with complete response or partial response)
Tidsram: At the time of progression or death or at 2 year follow up
|
At the time of progression or death or at 2 year follow up
|
Overall survival
Tidsram: At the time of death or at 2 year follow up
|
At the time of death or at 2 year follow up
|
Duration of response
Tidsram: At the time of progression or at 2 year follow up
|
At the time of progression or at 2 year follow up
|
Clinical benefit rate
Tidsram: At the time of progression or death or at 2 year follow up
|
At the time of progression or death or at 2 year follow up
|
Time to response
Tidsram: At the time of response or at 2 year follow up
|
At the time of response or at 2 year follow up
|
Safety assessed by recording of adverse events, physical examinations, vital signs, laboratory assessments and electrocardiograms (ECGs)
Tidsram: Up to 30 days after last subject discontinues treatment
|
Up to 30 days after last subject discontinues treatment
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Sr. Medical Director, Astellas Pharma Global Development
- Huvudutredare: United Kingdom Principal Investigator, Royal Bournemouth Hospital
- Huvudutredare: Poland Principal Investigator, Centrum Onkologii-Instytut im.
- Huvudutredare: Ireland Principal Investigator, St. Vincent's University Hospital
- Huvudutredare: Germany Principal Investigator, Luisenkrankenhaus Duesseldorf
- Huvudutredare: Czech Republic Principal Investigator, Thomayer Faculty Hosptial L.G.
- Huvudutredare: Belgium Principal Investigator, Institut Jules Bordet - Medical Oncology and Translational Research
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 155-CL-036
- 2009-012439-14 (EudraCT-nummer)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Bröstcancer
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital och andra samarbetspartnersAvslutadDen kliniska tillämpningsguiden för Conebeam Breast CTKina
-
ETOP IBCSG Partners FoundationAvslutadBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAvslutadBreast Cancer Invasive NosSpanien
-
Pomeranian Medical University SzczecinMaria Sklodowska-Curie National Research Institute of Oncology; Regional...OkändBRCA1-mutation | Breast Cancer Invasive NosPolen
-
University Health Network, TorontoAvslutadBreast Cancer Invasive Nos | Primär invasiv bröstcancerKanada
-
Novartis PharmaceuticalsAvslutadMetastaserad bröstcancer (MBC) | Locally Advance Breast Cancer (LABC)Storbritannien, Spanien
-
McMaster UniversityCanadian Breast Cancer FoundationAvslutadBreast Cancer Invasive Nos | Steg 0 BröstkarcinomKanada
Kliniska prövningar på YM155
-
Astellas Pharma IncAvslutadLungcancer | Karcinom, icke-småcellig lunga | Lungcancer | Icke-småcelligt lungkarcinom | Cancer i lunganTyskland, Tjeckien, Nederländerna
-
Astellas Pharma IncAvslutad
-
Astellas Pharma IncAvslutadMelanom | Non-Hodgkins lymfom | ProstatacancerFörenta staterna
-
Astellas Pharma IncAvslutadLymfom, storcelligt, diffust | Lymfom, B-cellsrefraktärFrankrike, Spanien, Förenta staterna, Kanada
-
Astellas Pharma IncAstellas Pharma US, Inc.AvslutadMelanomFörenta staterna
-
Astellas Pharma IncAstellas Pharma US, Inc.AvslutadProstatacancer | Cancer i prostata | Prostatacancer | ProstatacancerNederländerna, Förenta staterna, Storbritannien
-
Astellas Pharma IncAvslutadMelanomFörenta staterna, Kanada
-
Astellas Pharma IncAvslutadNon-Hodgkins lymfomFörenta staterna, Frankrike, Spanien, Storbritannien
-
National Cancer Institute (NCI)Avslutad